Product Description
Mechanisms of Action: D2 Antagonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral,Intravenous
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: AstraZeneca
Company Location: CAMBRIDGE X0 CB2 0AA
Company CEO: Pascal Soriot
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 4: Anorexia|Substance Abuse Unspecified|Bulimia Nervosa|Malnutrition
Phase 2: Healthy Volunteers|Parkinson's Disease
Phase 1: Traumatic Brain Injury|Depressive Disorder|Opioid-Related Disorders|Obesity|Overweight
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|
| NCT03999190 | N/A |
Withdrawn |
Schizophrenia |
2025-07-01 |
2020-06-01 |
Patient Enrollment|Primary Endpoints|Treatments|Trial Status |
|
| 2015P002520 | N/A |
Completed |
Depressive Disorder, Major |
2021-03-01 |
2021-08-05 |
Primary Endpoints |
|
| R01MH079397 | N/A |
Completed |
Anorexia |
2015-07-01 |
2019-03-18 |
Treatments |
|
| Motor Memory | N/A |
Completed |
Parkinson's Disease |
None |
2019-03-22 |
Treatments |
|
| 17-AA-0114 | P1 |
Recruiting |
Opioid-Related Disorders |
2025-12-31 |
2024-10-16 |
Patient Enrollment|Primary Endpoints|Treatments |
|
| 14-N-0083 | P1 |
Completed |
Traumatic Brain Injury |
2024-02-13 |
2024-09-21 |
Patient Enrollment|Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments|Trial Status |
|
| 18-DK-0132 | P1 |
Completed |
Overweight|Obesity |
2022-03-31 |
2023-07-12 |
Primary Endpoints |
|
| PET | P1 |
Completed |
Depressive Disorder |
None |
2019-03-18 |
Treatments |
|
| 2011-003071-11 | P2 |
Completed |
Healthy Volunteers |
2014-01-31 |
2025-05-06 |
Treatments|Trial Status |
|
| 2007-002496-14 | P2 |
Terminated |
Parkinson's Disease |
2008-03-27 |
2022-03-12 |
Treatments |
|
| R01MH092793 | P4 |
Completed |
Anorexia|Malnutrition|Bulimia Nervosa |
2017-12-31 |
2020-04-28 |
Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments |
|
| 2014-001284-12 | P4 |
Active, not recruiting |
Substance Abuse Unspecified |
None |
2022-03-13 |
Treatments |